Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
54.50
+0.30 (0.54%)
Mar 3, 2026, 9:48 AM EST - Market open
Spruce Biosciences Revenue
Spruce Biosciences had revenue of $697.00K in the twelve months ending September 30, 2025, down -90.18% year-over-year. In the year 2024, Spruce Biosciences had annual revenue of $4.91M, down -51.32%.
Revenue (ttm)
$697.00K
Revenue Growth
-90.18%
P/S Ratio
83.24
Revenue / Employee
$77,444
Employees
9
Market Cap
58.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.91M | -5.18M | -51.32% |
| Dec 31, 2023 | 10.09M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 30.91M |
| ImmuCell | 27.77M |
| TScan Therapeutics | 8.42M |
| Radiopharm Theranostics | 8.20M |
| Alterity Therapeutics | 4.96M |
| Lipocine | 4.32M |
| BeyondSpring | 1.88M |
| Mereo BioPharma Group | 500.00K |
SPRB News
- 18 hours ago - Spruce Biosciences to Present at Upcoming Investor Conferences in March - Business Wire
- 13 days ago - Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 13 days ago - Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Business Wire
- 25 days ago - Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 4 weeks ago - Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - Business Wire
- 4 weeks ago - Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - Business Wire
- 6 weeks ago - Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - PRNewsWire
- 7 weeks ago - Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - Business Wire